Towards Healthcare
Pre-Dx Oncology Market Tends and Companies

Pre-Dx Oncology Market Shaping Future Diagnostics and Care

The global Pre-Dx oncology market is growing with rising cancer incidence and advanced early detection technologies. North America led with 45% share in 2024, while Asia Pacific is fastest-growing. Liquid biopsy tests accounted for 40% revenue, MCED tests show high CAGR, and NGS made up 38% of technology revenue. Blood and urine are key sample types, with clinical labs contributing 40% revenue. Top companies include Illumina, Thermo Fisher, and Freenome. The report covers competitive analysis, value chain, trade data, and manufacturers.

Content

  • Last Updated: 17 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The pre-dx oncology market projected to grow rapidly through 2034, fueled by innovation and changing consumer preferences.

North America is currently leading the pre-dx oncology market due to growing concerns about cancer cases.

The pre-dx oncology market includes five segments: test/solution type, technology, sample, end-user, and region.

The doctor usually receives the results in two weeks.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC, National Cancer Institute, Department of Biotechnology.
Any Questions